NANOV Stock Overview
Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for hematological cancers in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nordic Nanovector ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.00 |
| 52 Week High | NOK 3.34 |
| 52 Week Low | NOK 0.65 |
| Beta | 1.61 |
| 1 Month Change | 167.11% |
| 3 Month Change | 149.44% |
| 1 Year Change | -22.20% |
| 3 Year Change | -90.38% |
| 5 Year Change | -96.64% |
| Change since IPO | -92.86% |
Recent News & Updates
Recent updates
Can Nordic Nanovector (OB:NANOV) Afford To Invest In Growth?
Aug 30
Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?
Nov 09We Think Nordic Nanovector (OB:NANOV) Needs To Drive Business Growth Carefully
Jul 02Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?
Jan 06Shareholder Returns
| NANOV | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -18.3% | 0.3% | 1.4% |
| 1Y | -22.2% | -67.0% | 0.3% |
Return vs Industry: NANOV exceeded the Norwegian Biotechs industry which returned -61.9% over the past year.
Return vs Market: NANOV underperformed the Norwegian Market which returned -0.1% over the past year.
Price Volatility
| NANOV volatility | |
|---|---|
| NANOV Average Weekly Movement | 39.3% |
| Biotechs Industry Average Movement | 14.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in NO Market | 11.1% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: NANOV's share price has been volatile over the past 3 months.
Volatility Over Time: NANOV's weekly volatility has increased from 24% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 18 | Alf Bjornseth | www.nordicnanovector.com |
Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for hematological cancers in Norway. The company’s lead product candidate is Betalutin, a CD37-targeting radioimmunotherapy for the treatment of patients with non-hodgkin lymphoma. Its preclinical development products include Humalutin for treatment of non-Hodgkin’s lymphoma; Alpha37, a CD37-targeting radioimmunotherapy for treating chronic lymphatic leukemia; and Multiple fully humanized anti-CD37 antibodies for treatment of haematological cancers and autoimmune diseases.
Nordic Nanovector ASA Fundamentals Summary
| NANOV fundamental statistics | |
|---|---|
| Market cap | NOK 231.84m |
| Earnings (TTM) | -NOK 311.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs NANOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANOV income statement (TTM) | |
|---|---|
| Revenue | NOK 0 |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 0 |
| Other Expenses | NOK 311.24m |
| Earnings | -NOK 311.24m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Aug 31, 2023
| Earnings per share (EPS) | -2.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NANOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/04 11:28 |
| End of Day Share Price | 2023/07/04 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nordic Nanovector ASA is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Patrik Ling | DNB Markets |
| Peter Welford | Jefferies LLC |